or Try an Advanced Search...

    Advanced Solid Tumors Stocks List

    Symbol Grade Name % Change
    CLRB F Cellectar Biosciences, Inc. -9.04
    RLAY F Relay Therapeutics, Inc. -1.84
    STTK F Shattuck Labs, Inc. 3.17
    PPBT F Purple Biotech Ltd. 2.75
    SLRX F Salarius Pharmaceuticals, Inc. 2.17
    HOWL F Werewolf Therapeutics, Inc. -2.34
    ADCT F ADC Therapeutics SA -3.74
    IMRX F Immuneering Corporation 13.33
    CRDF D Cardiff Oncology, Inc. 1.55
    CASI D CASI Pharmaceuticals, Inc. -4.98
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Solid Tumors Cancer Clinical Medicine Medicine Biotechnology Oncology Antineoplastic Drugs Biopharmaceutical Cancer Treatment Life Sciences Treatment Of Cancer Chemotherapy Drugs Health Sciences Leukemia Lymphoma Metastatic Solid Tumors Ovarian Cancer Pharmaceutical Prostate Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Advanced Solid Tumors stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 1.83
    LRNZ A TrueMark Technology, AI & Deep Learning ETF 0.98
    CANC D Tema Oncology ETF 0.72
    BBC D Virtus LifeSci Biotech Clinical Trials ETF 0.57
    SCDS B JPMorgan Fundamental Data Science Small Core ETF 0.32
    View all Advanced Solid Tumors ETFs...
    Compare ETFs
    Compare BBC to SCDS Compare CNCR to BBC Compare LRNZ to BBC

        Advanced Solid Tumors Stocks Recent News

        Date Stock Title
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 19 CLRB Q3 2024 Cellectar Biosciences Inc Earnings Call
        Nov 18 CLRB Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
        Nov 18 CLRB Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03
        Nov 18 CLRB Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
        Nov 18 CLRB Earnings Scheduled For November 18, 2024
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 16 STTK Shattuck Labs Third Quarter 2024 Earnings: Beats Expectations
        Nov 15 CLRB Cellectar Biosciences Q3 2024 Earnings Preview
        Nov 15 CASI CASI Pharmaceuticals reports Q3 results
        Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
        Nov 15 STTK Shattuck Labs sees cash runway into 2027
        Nov 15 PPBT Purple Biotech GAAP EPS of -$0.39
        Nov 15 PPBT Purple Biotech Reports Third Quarter 2024 Financial Results
        Nov 15 SLRX Salarius: Q3 Earnings Snapshot
        Nov 14 IMRX Immuneering GAAP EPS of -$0.49
        Nov 14 CLRB Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
        Nov 14 STTK Shattuck Labs GAAP EPS of -$0.33 beats by $0.06, revenue of $3M
        Nov 14 STTK Shattuck Labs Reports Third Quarter 2024 Financial Results and Recent Business Highlights
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Solid Tumors Cancer Biotechnology Clinical Medicine Life Sciences Medicine Treatment Of Cancer Biopharmaceutical Cancer Treatment Lymphoma Oncology Ovarian Cancer Antineoplastic Drugs Autoimmune Disease Drugs Health Sciences Leukemia Metastatic Solid Tumors Pharmaceutical Prostate Cancer
        Advanced Solid Tumors

        Advanced solid tumors are cancerous tumors that have spread beyond the original site of the tumor and have become more difficult to treat. These tumors are often referred to as metastatic or stage IV tumors. Advanced solid tumors can affect any part of the body and can be caused by a variety of different types of cancer. Treatment options for advanced solid tumors may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and/or clinical trials.

        Browse All Tags